Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotyping Clear all
Completed Not applicable Interventional Results available

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

NCT02508116
View directory record Official record
Conditions
Acute Coronary Syndrome, Cardiovascular Diseases
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 21, 2026, 5:38 AM EDT
Withdrawn Early Phase 1 Interventional

CYP2C19 Genotype Predictor of Gastric Acid Suppression

NCT01824199
View directory record Official record
Conditions
Esophagitis
Interventions
Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 21, 2026, 5:38 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Mechanism of Conserved Ancestral Haplotype in SCA10

NCT04495426
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 10
Interventions
Non-interventional study
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Communicating Risk Information for Obesity

NCT01355224
View directory record Official record
Conditions
Obesity
Interventions
Genetic, Lifestyle
Genetic · Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 21, 2026, 5:38 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

NCT01467479
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 21, 2026, 5:38 AM EDT
Terminated Not applicable Interventional Results available

Pharmacogenetic Prediction of Metoprolol Effectiveness

NCT02293096
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate, Genotyping, CYP2D6 Phenotyping
Drug · Genetic · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 80 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 21, 2026, 5:38 AM EDT
Not listed No phase listed Observational

Pharmacogenomics of Warfarin in Hispanics and Latinos

NCT02972385
View directory record Official record
Conditions
Thrombosis, Hemorrhage
Interventions
Mouthwash sample, Blood Draw
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543
View directory record Official record
Conditions
Diabetes, Coronary Artery Disease
Interventions
ALT-2074
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensitive Periods in Early Flavor Learning

NCT00994747
View directory record Official record
Conditions
Healthy
Interventions
Nutramigen (Flavor and Type of Infant Formula), Enfamil, milk-based formula
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
2 Weeks to 4 Weeks
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 21, 2026, 5:38 AM EDT
Withdrawn Phase 2 Interventional

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

NCT01629732
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, BMS-986094, Ribavirin, Placebo for BMS-986094
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 21, 2026, 5:38 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Risk Feedback on Behavioral Trajectories

NCT07657221
View directory record Official record
Conditions
Healthy, Alcohol Consumption
Interventions
PHEN feedback, PHEN+GENE Feedback, Control
Behavioral · Genetic · Other
Lead sponsor
University of Southern California
Other
Eligibility
17 Years to 25 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed No phase listed Observational

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

NCT04166149
View directory record Official record
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
Interventions
dd-cfDNA Blood Test
Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

NCT02138617
View directory record Official record
Conditions
Colon Cancer
Interventions
5-Fluorouracil, Leucovorin, Irinotecan, Bevacizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

NCT04903626
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir (GLE/PIB)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

NCT04300920
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Fernando J Martinez
Other
Eligibility
40 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed No phase listed Observational

Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients

NCT02771808
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
biomarker samples
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

NCT01859962
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

NCT01074008
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

NCT02939989
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
8
States / cities
Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

NCT03501550
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
CDI-31244, SOF/VEL
Drug
Lead sponsor
Cocrystal Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 21, 2026, 5:38 AM EDT
Terminated No phase listed Observational

Development and Validation of a Model to Predict Fast Progression in Glaucoma

NCT04454190
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions
Collection of genetic material
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
40 Years to 90 Years
Enrollment
1,152 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 21, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Screening Strategies Among High-risk Populations for Anal Cancer

NCT06628570
View directory record Official record
Conditions
Neoplasms, HPV-Related Anal Squamous Cell Carcinoma
Interventions
HRA + Biopsy, Anal Cytology, Genotyping of anal hrHPV infection, CINtec®PLUS
Diagnostic Test
Lead sponsor
Lisa Flowers
Other
Eligibility
30 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Three Interacting Single Nucleotide Polymorphisms (SNPs) and the Risk of Preterm Birth in Black Families

NCT00675753
View directory record Official record
Conditions
Premature Birth
Interventions
Blood spot specimens will be drawn
Genetic
Lead sponsor
University of Miami
Other
Eligibility
1 Minute to 28 Days
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 21, 2026, 5:38 AM EDT